(Q37801855)

23 August 2017

title

Gene therapy: a viable therapeutic strategy for Parkinson's disease? (English)

1 reference

23 August 2017

0 references

1 reference

2

Thomas Foltynie

1 reference

23 August 2017

Alexander L Berry

1

1 reference

23 August 2017

publication date

21 October 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

258

1 reference

23 August 2017

issue

2

1 reference

23 August 2017

page(s)

179-188

1 reference

Drug treatment of Parkinson's disease

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Pathophysiology of levodopa-induced dyskinesia: potential for new therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Functional recovery in parkinsonian monkeys treated with GDNF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Neurturin shares receptors and signal transduction pathways with glial cell line-derived neurotrophic factor in sympathetic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Biopterin in human brain and urine from controls and parkinsonian patients: Application of a new radioimmunoassay

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Results from a phase I safety trial of hAADC gene therapy for Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Tetrahydrobiopterin in Striatum: Localization in Dopamine Nerve Terminals and Role in Catecholamine Synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Pathological synchronization in Parkinson's disease: networks, models and treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Subthalamic GAD gene therapy in a Parkinson's disease rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Gene therapy for dopamine replacement in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Scientific rationale for the development of gene therapy strategies for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Non-motor symptoms of Parkinson's disease: diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Staging of brain pathology related to sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Neuropathology of non-motor features of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Visuo-spatial short-term recognition memory and learning after temporal lobe excisions, frontal lobe excisions or amygdalo-hippocampectomy in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

The PINK1/Parkin pathway: a mitochondrial quality control system?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Neuronal specificity of alpha-synuclein toxicity and effect of Parkin co-expression in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Neuroprotective effect of long-term NDI1 gene expression in a chronic mouse model of Parkinson disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Interaction map and selection of microRNA targets in Parkinson's disease-related genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Human alpha-iduronidase gene transfer mediated by adeno-associated virus types 1, 2, and 5 in the brain of nonhuman primates: vector diffusion and biodistribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Gene therapy delivers an alternative approach to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

The epidemiology of dementia associated with Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Non-motor symptoms: identification and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Sleep dysfunction and role of dysautonomia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Abnormal sleep and sleepiness in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Bladder and bowel dysfunction in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Prevalence of bladder dysfunction in Parkinsons disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Non-motor symptoms in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Genitourinary dysfunction in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Erectile dysfunction in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Sialorrhea in Parkinson's disease: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Prevalence and definition of drooling in Parkinson's disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Constipation in idiopathic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Neuropsychiatric symptoms in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Mitochondrial dysfunction and oxidative damage in parkin-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Molecular pathogenesis of Parkinson disease: insights from genetic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Phosphorylation of parkin by Parkinson disease-linked kinase PINK1 activates parkin E3 ligase function and NF-kappaB signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-010-5796-9

Gastrointestinal dysfunction in Parkinson's disease

21 January 2018

1 reference

12 December 2020

Symptoms of autonomic failure in Parkinson's disease: prevalence and impact on daily life

1 reference

12 December 2020

Gastrointestinal symptoms in Parkinson's disease

1 reference

12 December 2020

The nighttime problems of Parkinson's disease.

1 reference

12 December 2020

Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat

1 reference

12 December 2020

Recombinant adeno-associated viral vectors bring gene therapy for Parkinson's disease closer to reality

1 reference

12 December 2020

Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects.

1 reference

12 December 2020

Dopamine agonist therapy in early Parkinson's disease

1 reference

12 December 2020

Sleep disorders in Parkinson's disease

1 reference

12 December 2020

Depression in Parkinson's disease

1 reference

12 December 2020

Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons

1 reference

12 December 2020

Pain in Parkinson's disease

1 reference

12 December 2020

Sleep disorders in Parkinson's disease

1 reference

12 December 2020

Understanding microRNAs in neurodegeneration

1 reference

12 December 2020

10.1007/S00415-010-5796-9

Identifiers

DOI

1 reference

23 August 2017

1 reference